Emphysema Devices Search for Breathing Room
Interventional pulmonology is a burgeoning field for medical device manufacturers. It is ripe with opportunities to develop minimally invasive solutions for patients with chronic progressive lung disease. Emphysema, which afflicts close to 2% of the world's population, is a prime target. With an opportunity as large as this driving innovation and investment, the right combination of technology and clinical trial design could spell blockbuster success for medtech companies.
You may also be interested in...
Minimally invasive emphysema devices have seen their ups and downs over the years, but despite technological and regulatory challenges, VCs continue to fund these devices, with investments driven by the market opportunity, huge unmet clinical need, and promising technologies.
Rox Medical is taking an unusual approach to treating COPD by introducing a vascular device that increases oxygen delivery to tissue and cardiac output. The potential has investors' hearts racing as well.
For the past decade, venture capitalists have invested in companies that are developing new technologies to treat late-stage chronic obstructive pulmonary disorders.Despite hundreds of millions in venture capital dollars, the companies have made little progress in bringing these products to market in the US. But this band of start-ups is taking the fight to the streets - of Europe.